RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All News and Research Articles

IV infused golimumab may improve function and disease management in patients suffering from inflammatory and joint pain.
In 2015, PPM published “Methadone for Pain Management,”1 which cited that one-third of opioid-implicated deaths were caused by methadone.
Patients who take opioids and drink coffee less pain-related symptoms and depressiion, and higher physical function than patients taking opioids who avoid caffeine.
The first, wearable, noninvasive neurostimulation device, the Bridge, reduced symptoms of opioid withdrawal to achieve 89% success in transitioning to long-term care.
New pain management formulations may impact opioid prescribing and usage: Scripps looks into the G protein and beta-arestin pathways, including fentanyls's role, Daiichi Sankyo releases MorphaBond ER, and FDA moves forward two buprenorphine products to treat opioid use disorder.
An interactive wearable device with an app will be studied to its efficacy in reducing chronic pain to lessen reliance on medication.
Investigational biologic from Novartis (Cosentyx) may reduce joint pain and tenderness in patients with psoriatic arthritis.
A second Phase 3 trial of tenapanor (T3MPO-2)1 shows promise for relieving symptoms in patients with constipation-predominant irritable bowel syndrome (IBS-C).
A new sufentanil sublingual tablet may provide clinicians and patients with simpler means of dosing and drug delivery.
A new study shows significant correlations between irritable bowel diseases (IBD) such as Crohn’s disease and colitis, and risk of developing gallstones and kidney stones.
Two new therapies promise improved management for the pain and itching associated with eczema by targeting the inflammatory response of atopic dermatitis.
Only 1/3 of adults with inflammatory bowel disease seek medical attention, yet a new approach for IBS with diarrhea using an anti-bacterial seems likely to address symptoms more effectively than usual care.
Pain is the most common report among chronic pancreatitis (CP), and it is often severe, leading to detrimental effects on quality of life, Darwin L. Conwell, MD, MS, explained at the 2017 World Congress of Gastroenterology.1 CP pain “can be constant or intermittent,” Dr. Conwell told Practical Pain Management (PPM).  Dr.
While patients commonly present with a triad of complaints—chronic diarrhea, bloating, and abdominal pain, each symptom should be addressed separately according to a Mayo Clinic professor who presented at the World Congress on Gastroenterology.
SHOW MAIN MENU
SHOW SUB MENU